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CASE REPORT
Nitrofurantoin-induced radiation recall dermatitis
Ian Garrahy and Daniel Forman
Department of Medicine, Reading Hospital, Reading, PA, USA
ABSTRACT
Radiation recall dermatitis (RRD) is an inflammatory skin reaction that develops in a previously
quiescent radiation field triggered most commonly by chemotherapy, particularly anthracy-
clines and taxanes. Radiation-recall dermatitis secondary to antibiotic therapy is quite rare.
The patient is 61-year-old female with a history of squamous cell carcinoma of the left breast
treated with neoadjuvant carboplatin, paclitaxel, and anthracycline chemotherapy followed
by surgery and subsequent whole breast radiation 6040 cGy. Eight years after completion of
her radiation she developed diffuse redness of the left breast after two doses of nitrofur-
antoin taken for a urinary tract infection. On examination, vital signs were stable and she had
an erythematous and excoriated rash on her left breast that clinically appeared to be cellulitis.
Given her clinical history, coupled with the temporal relationship of starting an antibiotic,
strong consideration was given for antibiotic-induced RRD. Nitrofurantoin was discontinued,
and the rash resolved completely within several days. This case demonstrates an example of
RRD which is the development of an acute inflammatory skin reaction of a previously
irradiated area most commonly triggered by chemotherapeutic agents. This case highlights
antimicrobial therapy as a rare cause of RRD and underscores the importance of considering
RRD in a patient presenting with an acute rash over a previously irradiated area while on
antimicrobial therapy.
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Radiation recall dermatitis (RRD) is an acute inflam-
matory skin reaction that occurs over a previously
quiescent irradiated field after administration of cer-
tain medications. Most cases of RRD are associated
with chemotherapy, particularly the anthracyclines
and taxanes [1]. The first radiation recall reaction
was described by D’Angio in 1959. It involved dacti-
nomycin which produced a reaction on previously
irradiated skin that was identical to the reaction initi-
ally produced by radiation [2]. However, RRD has
also been reported with tamoxifen, simvastatin, and
anti-tuberculosis medication [3–5]. Although antibio-
tic-induced RRD is rare, associations between quino-
lones and RRD have been reported. We present a case
of a women who developed RRD after administration
of nitrofurantoin.
2. Case description
A 53-year-old female developed a urinary tract infec-
tion and was started on nitrofurantoin 100 mg twice
a day for 5 days by her primary care physician. After
two doses of nitrofurantoin, she developed redness and
irritation over her left breast (see Figure 1). The patient
had had no sunlight exposure to the area nor any
changes to her other medications. The patient’s only
known allergy was hives to dye contrast. On
examination, vital signs were stable, and she had
a sharply demarcated erythematous and excoriated
rash on her left breast.
The patient has a prior history of squamous cell
carcinoma of the left breast treated with neoadjuvant
carboplatin, paclitaxel, and anthracycline chemother-
apy followed by surgery and subsequent whole breast
radiation 6040 cGy. The breast cancer history began
in December 2010 when she developed a left axillary
mass. CT chest revealed mildly prominent left axillary
lymph nodes. With concern for an occult left-sided
breast cancer, a follow-up MRI of the bilateral breasts
was completed which revealed a 2.2 × 0.9 x 1.7 cm
area of heterogeneous non-mass like enhancement
within the 2:00 to 3:00 position of the left breast.
She underwent excision of the left axillary mass.
Pathology revealed poorly differentiated squamous cell
carcinoma of the left breast. The tumor was negative for
both the estrogen and the progesterone receptors. She
was treated with neoadjuvant chemotherapy with carbo-
platin, paclitaxel, and anthracycline chemotherapy. A left
lumpectomy and axillary node dissection was performed
in May 2011. All 18 axillary nodes were negative for
metastasis, indicating complete response. Finally, she
was treated with adjuvant radiation 6040 cGy in 33 frac-
tions over 6 weeks. She tolerated the radiation course well
and only developedmild erythema at the site of the breast
irradiation.
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The patient’s rash that occurred following two
doses of antimicrobial therapy corresponded to the
prior radiation treatment portals. Given the temporal
relationship of the rash with the antibiotic adminis-
tration, the patient was felt to have RRD to nitrofur-
antoin. Other differential diagnoses included cellulitis
and allergic contact dermatitis. However, the patient
was afebrile, without leukocytosis, and her only
known allergy was to dye contrast. Nitrofurantoin
was immediately discontinued, and she was pre-
scribed oral trimethoprim-sulfamethoxazole 160 mg
TMP/800 mg SMX twice a day for three days. The
rash quickly resolved within one week.
3. Discussion
This case demonstrates an example of RRD, which is
an inflammatory reaction of a previously irradiated
area precipitated by drug administration [6]. There is
a wide variety of chemotherapy drugs known to cause
RRD, particularly anthracyclines and taxanes. There is
growing evidence suggesting the association of noncy-
totoxic medications with RRD, including tamoxifen,
simvastatin, antitubercular drugs. There have been
case reports also documenting the association of the
antibiotics with RRD, including quinolones, and azi-
thromycin [7–9]. Our patient represents, to our knowl-
edge, the first case of this rare skin reaction to this
frequently used antibiotic, nitrofurantoin.
There have been a variety of mechanisms hypothe-
sized for RRD caused by noncytotoxic agents; epithelial
stem cell inadequacy and/or sensitivity, vascular
damage, and idiosyncratic drug hypersensitivity reac-
tions [10]. Our patient’s prompt improvement in
symptoms with the discontinuation of nitrofurantoin
supports an idiosyncratic drug hypersensitivity reaction
as a likely cause. Such reactions are likely not linked to
the immune system. The suggestion is that certain
drugs trigger non-immune inflammatory pathways in
patients whose inflammatory response threshold has
been lowered by radiation. Radiation may induce cells
to secrete low levels of cytokines, such as tumor necro-
sis factor α, that are responsible for an inflammatory
response [9]. When a triggering agent is introduced, the
cytokines are upregulated, causing a recall reaction.
The present case report is the fourth involving
a radiation recall reaction associated with antibiotic
therapy. The first reported radiation recall reaction
that occurred with antibiotic therapy was with gatiflox-
acin [7]. There have also been case reports with levo-
floxacin and azithromycin-induced RRD. The antibiotic
nitrofurantoin, which provoked the reaction, does not
belong to the class of fluoroquinolones. Nitrofurantoin
is frequently used to treat urinary tract infections due to
its convenient oral use, low side effect profile, and low
cost. It is important for providers to know that in
patients who have been treated with radiation, that
a radiation recall reaction can occur with commonly
prescribed antibiotics, including nitrofurantoin.
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